Edward Nash
Stock Analyst at Canaccord Genuity
(n/a)
# 4,797
Out of 4,829 analysts
81
Total ratings
n/a
Success rate
-27.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $394 → $420 | $300.76 | +39.65% | 9 | May 2, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $64 | $20.18 | +217.15% | 1 | Apr 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $21.54 | +118.20% | 10 | Apr 10, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $130 → $142 | $72.14 | +96.84% | 7 | Apr 1, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.61 | +1,368.19% | 2 | Feb 26, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $44 → $72 | $67.53 | +6.62% | 9 | Feb 12, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.47 | +172.11% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $41.53 | +75.78% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $39.48 | +125.43% | 1 | Nov 25, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $1.21 | +1,057.02% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.13 | +607.96% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $3.55 | +463.38% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $2.61 | +206.51% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.73 | +355.76% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.24 | -10.71% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.26 | +14,185.71% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $36.09 | +127.21% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $2.71 | +2,852.03% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $13.15 | +265.02% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.60 | +11,507.14% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $394 → $420
Current: $300.76
Upside: +39.65%
Celldex Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $64
Current: $20.18
Upside: +217.15%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $21.54
Upside: +118.20%
Corcept Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $130 → $142
Current: $72.14
Upside: +96.84%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.61
Upside: +1,368.19%
Verona Pharma
Feb 12, 2025
Maintains: Buy
Price Target: $44 → $72
Current: $67.53
Upside: +6.62%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.47
Upside: +172.11%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $41.53
Upside: +75.78%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $39.48
Upside: +125.43%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $1.21
Upside: +1,057.02%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.13
Upside: +607.96%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.55
Upside: +463.38%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $2.61
Upside: +206.51%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.73
Upside: +355.76%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.24
Upside: -10.71%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.26
Upside: +14,185.71%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $36.09
Upside: +127.21%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $2.71
Upside: +2,852.03%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $13.15
Upside: +265.02%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.60
Upside: +11,507.14%